Business Context and Reporting Period
Company: Acrivon Therapeutics, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: February 27, 2026
Event: Regulation FD Disclosure regarding a Key Opinion Leader (KOL) panel discussion held during the European Society of Gynecological Oncology (ESGO) Congress in Copenhagen, Denmark.
Key Financial Metrics
This filing is a current report regarding a clinical event and does not contain financial statements. The filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes
No material financial changes are reported in this document. The primary update is the presentation of interim clinical data for the company's lead asset, ACR-368, specifically from the Phase 2b registrational-intent trial arms.
Outlook, Commentary, and Risks
- Management Commentary: The company hosted a live webcast featuring a KOL panel to discuss interim data from the ACR-368 Phase 2b trial. The discussion focused on the potential of ACR-368 to address unmet patient needs in endometrial cancer, with specific emphasis on the serous sub-type.
- Future Plans: The panel included an overview of future plans for the asset, though specific timelines or milestones were not detailed in the summary text.
- Legal Disclaimer: The information provided in Item 7.01 and the attached slides (Exhibit 99.1) is not deemed "filed" under Section 18 of the Exchange Act and is not incorporated by reference into other filings unless expressly stated.
Investor Verification Checklist
- Review Exhibit 99.1 (KOL Panel Slides) for specific interim clinical data points and statistical significance regarding ACR-368.
- Verify the specific endpoints and patient population details for the serous sub-type of endometrial cancer discussed in the panel.
- Monitor subsequent filings for formal data readouts or regulatory interactions following the ESGO Congress presentation.
- Check the company's cash runway and burn rate in the most recent 10-Q or 10-K, as this 8-K does not provide liquidity updates.